Colon Pharmaceuticals announced that the company released its 2026 semi-annual report, achieving operating revenue of 8.839 billion yuan, a year-on-year decrease of 2.7%; net profit attributable to shareholders of listed companies was 1,128 billion yuan, an increase of 12.71% over the previous year. The company plans to pay a cash dividend of 1.26 yuan for every 10 shares. The company's Q2 net profit was 674 million and Q1 net profit was 454 million. Based on this calculation, Q2 net profit increased 48% month-on-month.

Colon Pharmaceuticals announced that the company released its 2026 semi-annual report, achieving operating revenue of 8.839 billion yuan, a year-on-year decrease of 2.7%; net profit attributable to shareholders of listed companies was 1,128 billion yuan, an increase of 12.71% over the previous year. The company plans to pay a cash dividend of 1.26 yuan for every 10 shares. The company's Q2 net profit was 674 million and Q1 net profit was 454 million. Based on this calculation, Q2 net profit increased 48% month-on-month.